Arca Biopharma (ABIO) Earns Media Sentiment Score of -0.04

Media headlines about Arca Biopharma (NASDAQ:ABIO) have trended somewhat negative this week, according to Accern. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Arca Biopharma earned a coverage optimism score of -0.04 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 47.0705858959414 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

ABIO traded down $0.02 during trading on Thursday, hitting $0.51. The stock had a trading volume of 257,838 shares, compared to its average volume of 897,601. Arca Biopharma has a twelve month low of $0.45 and a twelve month high of $2.71.

Arca Biopharma (NASDAQ:ABIO) last announced its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.20).

A number of equities analysts have recently issued reports on ABIO shares. Ascendiant Capital Markets started coverage on shares of Arca Biopharma in a research note on Tuesday, February 27th. They set a “buy” rating and a $2.00 price objective on the stock. ValuEngine upgraded shares of Arca Biopharma from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.

Arca Biopharma Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction.

Insider Buying and Selling by Quarter for Arca Biopharma (NASDAQ:ABIO)

Receive News & Ratings for Arca Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arca Biopharma and related companies with's FREE daily email newsletter.

Leave a Reply